Abstract
Background: The validity of experimentally induced panic attacks as a model to study the pathophysiology of panic disorder has been questioned. Unspecific, unpleasant and aversive effects as well as specific patterns of psychovegetative symptoms pointing to different subtypes of panic disorder patients have been observed. These findings raise the question of challenge paradigms as a valuable tool to identify different vulnerabilities in patients with panic disorder.
Methods: We compared the two most widely studied panicogenic drugs sodium lactate and cholecystokinine tetrapeptide (CCK-4) with placebo in 25 patients with panic disorder and matched healthy control subjects. Psychophysiological changes were measured using the Acute Panic Inventory (API) and visual analogue scales for anxiety and arousal. Results: In patients with panic disorder 18 out of 25 experienced a sodium lactate- or a CCK-4 induced panic attack. Lactate or CCK-4 induced symptoms and induced panic attacks were only correlated in healthy controls, but not in patients with panic disorder. Conclusion: The mechanisms of lactate and CCK-4 induced panic attacks are distinct in panic disorder patients but not in healthy controls. Different neurobiological vulnerabilities may be uncovered by different challenges.Keywords: Panic disorder, CCK-4, lactate, acute panic inventory, panicogenic activity
Current Pharmaceutical Design
Title:Distinct Panicogenic Activity of Sodium Lactate and Cholecystokinin Tetrapeptide in Patients with Panic Disorder
Volume: 18 Issue: 35
Author(s): Jens Plag, Katharina Gaudlitz, Elisabeth Zschucke, Alexander Yassouridis, Lena Pyrkosch, Andre Wittmann, Florian Holsboer and Andreas Strohle
Affiliation:
Keywords: Panic disorder, CCK-4, lactate, acute panic inventory, panicogenic activity
Abstract: Background: The validity of experimentally induced panic attacks as a model to study the pathophysiology of panic disorder has been questioned. Unspecific, unpleasant and aversive effects as well as specific patterns of psychovegetative symptoms pointing to different subtypes of panic disorder patients have been observed. These findings raise the question of challenge paradigms as a valuable tool to identify different vulnerabilities in patients with panic disorder.
Methods: We compared the two most widely studied panicogenic drugs sodium lactate and cholecystokinine tetrapeptide (CCK-4) with placebo in 25 patients with panic disorder and matched healthy control subjects. Psychophysiological changes were measured using the Acute Panic Inventory (API) and visual analogue scales for anxiety and arousal. Results: In patients with panic disorder 18 out of 25 experienced a sodium lactate- or a CCK-4 induced panic attack. Lactate or CCK-4 induced symptoms and induced panic attacks were only correlated in healthy controls, but not in patients with panic disorder. Conclusion: The mechanisms of lactate and CCK-4 induced panic attacks are distinct in panic disorder patients but not in healthy controls. Different neurobiological vulnerabilities may be uncovered by different challenges.Export Options
About this article
Cite this article as:
Plag Jens, Gaudlitz Katharina, Zschucke Elisabeth, Yassouridis Alexander, Pyrkosch Lena, Wittmann Andre, Holsboer Florian and Strohle Andreas, Distinct Panicogenic Activity of Sodium Lactate and Cholecystokinin Tetrapeptide in Patients with Panic Disorder, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530808
DOI https://dx.doi.org/10.2174/138161212803530808 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modeling and Simulation Approach to Support Dosing and Study Design Requirements for Treating HIV-Related Neuropsychiatric Disease with the NK1-R Antagonist Aprepitant
Current HIV Research Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series
Current Alzheimer Research Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia
Current Pharmaceutical Design Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Alzheimers Disease: Highlights from Research on Hormones, Growth Factors and Signaling Pathways (Debomoy K. Lahiri)]
Current Alzheimer Research Malaria-induced Alterations of Drug Kinetics and Metabolism in Rodents and Humans
Current Drug Metabolism Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Editorial [Hot-Topic:Physical and Chemical Agents Inducing Cell Death and Differentiation (Executive Editor: Roberta Di Pietro)]
Current Pharmaceutical Design Subject Index to Volume 4
Current Drug Metabolism Recent Development of G-Quadruplex Probes for Cellular Imaging
Current Topics in Medicinal Chemistry Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Paraneoplastic Neurological Syndromes - Diagnosis and Management
Current Pharmaceutical Design Combination Therapy in Fibromyalgia
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies
Current Drug Delivery Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Editorial [Hot Topic: Stem Cells and Tissue Regeneration (Executive Guest Editor: Roberta Di Pietro)]
Current Pharmaceutical Design